drugset / Trial / NCT07844551
ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for downstaging primary stage IVB oral squamous cell carcinoma or HPV16-negative oropharyngeal squamous cell carcinoma.
Timeline
- Start
- 2026-10-20
- Primary completion
- 2028-10-30
- Completion
- 2030-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Becotatug Vedotin | Other / unclassified | 2.3 mg/kg | Intravenous |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Pucotenlimab | Monoclonal antibody | 200 mg | Intravenous |